Stay updated on Talazoparib + Enzalutamide vs Enzalutamide in mCRPC Clinical Trial
Sign up to get notified when there's something new on the Talazoparib + Enzalutamide vs Enzalutamide in mCRPC Clinical Trial page.

Latest updates to the Talazoparib + Enzalutamide vs Enzalutamide in mCRPC Clinical Trial page
- CheckyesterdayChange DetectedAdded Contacts/Locations and Study Status sections to the history with entries dated 2025-12-08 and 2025-12-30, and removed the 2025-11-21 entry.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision: v3.3.3 was added to the page history; the HHS Vulnerability Disclosure and Revision: v3.3.2 entries were removed from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the Record History page; no study data, status, or content changes were made, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check44 days agoChange DetectedAdded Contacts/Locations and updated Study Status on 2025-11-21. Included Revision: v3.3.1.SummaryDifference0.2%

- Check51 days agoChange DetectedA generic government funding operating status notice was deleted from the page history, removing a broad operational message that does not affect trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check65 days agoChange DetectedThe record history shows updated versions with changes to study status and to contact/locations information. The latest version includes revised details and submission dates.SummaryDifference0.1%

Stay in the know with updates to Talazoparib + Enzalutamide vs Enzalutamide in mCRPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talazoparib + Enzalutamide vs Enzalutamide in mCRPC Clinical Trial page.